15.05.2018
Carl Zeiss Meditec AG DE0005313704
DGAP-News: Carl Zeiss Meditec increased revenue in the first six months of 2017/18 by 4.5 percent
DGAP-News: Carl Zeiss Meditec AG / Key word(s): Half Year Results
Carl Zeiss Meditec increased revenue in the first six months of 2017/18 by
4.5 percent
15.05.2018 / 06:58
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
__TOKEN__0__0__
Highest growth rate in Microsurgery strategic business unit
JENA, 15 May 2018
Carl Zeiss Meditec AG enjoyed further growth in the first six months of
2017/18, despite negative currency effects: Revenue increased by 4.5 percent
(adjusted for currency effects: 9.5 percent), to EUR613.7m (prior year:
EUR587.5m). Adjusted earnings before interest and taxes (EBIT) amounted to
around EUR90m (prior year: EUR89.1m). The adjusted EBIT margin was 14.7
percent (prior year: 15.2 percent). Earnings per share reached EUR0.63
(prior year: EUR0.76).
Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG, comments on the
first-half results: "Our business achieved significant organic growth in the
first six months; we are winning market shares in both strategic business
units. We are satisfied with the development of both the equipment business
and recurring sales."
Strongest growth in Microsurgery SBU
The Ophthalmic Devices strategic business unit increased its revenue by 3.7
percent (adjusted for currency effects: 8.6 percent), to EUR449.3m. This
increase is attributable to both products and solutions in ophthalmic
diagnostics, as well as to refractive laser systems and the strong demand
for premium and standard intraocular lenses.
The Microsurgery strategic business unit increased its revenue by 6.5
percent in the first six months of the current fiscal year (adjusted for
currency effects: 12.2 percent), to EUR164.4m, compared with EUR154.4m in
the same period of the prior year. The new products launched on the market
in the prior year in neuro and dental surgery performed well.
Solid currency-adjusted growth contributions from all regions
All regions exhibited a positive trend on a currency-adjusted basis, with
the highest growth rate of 10.0 percent (adjusted for currency effects: 11.4
percent) being achieved in the EMEA region. At almost EUR193.0m, revenue was
significantly higher than the prior-year figure of EUR175.4m. This increase
was attributable to the stable development in the core markets, Germany and
France, and to renewed growth in the UK and some markets of Southern Europe.
The reported revenue in the Americas region decreased by a slight 1.8
percent year-on-year, due to negative currency effects (adjusted for
currency effects: +8.1 percent), and amounted to EUR181.6m. The U.S.
business, in particular, developed strongly in local currency.
The APAC region achieved growth of 5.2 percent, to EUR239.1m. After
adjustment for currency effects, this corresponds to growth of 9.2 percent.
Once again, the largest contributions to growth came from China and South
Korea.
Adjusted earnings before interest and taxes (EBIT) amounted to around
EUR90m. The adjusted EBIT margin amounted to 14.7 percent (prior year: 15.2
percent). The decline is primarily attributable to negative currency effects
and targeted investments in research and development and sales and
marketing.
Earnings per share declined to EUR0.63 (prior year: EUR0.76). It was,
however, predominantly non-operating factors that contributed to this, such
as, in particular, the one-time proceeds in the prior year from the disposal
of assets at the Ontario site, and the increase in the number of outstanding
shares following the capital increase in March 2017.
Carl Zeiss Meditec AG expects revenue to be in a range of EUR1,230m to
EUR1,280m for fiscal year 2017/18. The EBIT margin is expected to be within
the range also forecast for the medium term, of 14 to 16 percent on an
adjusted basis.
Revenue by strategic business unit
All 6 Months 6 Months Change from Change from prior year
figures 2017/18 2016/17 prior year (adjusted for currency
in EURm effects)
Ophthalmi- 449.3 433.1 +3.7% +8.6%
c Devices
Microsurg- 164.4 154.4 +6.5% +12.2%
ery
Total 613.7 587.5 +4.5% +9.5%
Revenue by region
All 6 Months 6 Months Change from Change from prior year
figures 2017/18 2016/17 prior year (adjusted for currency
in EURm effects)
EMEA 193.0 175.4 +10.0% +11.4%
Americas 181.6 184.9 -1.8% +8.1%
APAC 239.1 227.2 +5.2% +9.2%
Total 613.7 587.5 +4.5% +9.5%
Contact for investors and press
Sebastian Frericks
Director Investor Relations Carl Zeiss Meditec AG
Phone: + 49 (0)3641 220-116
Email: [email protected]
www.zeiss.com/press
---------------------------------------------------------------------------
15.05.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: [email protected]
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
685679 15.05.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Carl Zeiss Meditec AG ISIN: DE0005313704 können Sie bei EQS abrufen
Medtech , 531370 , AFX , XETR:AFX